No significant difference was noted between the SMART and standard groups in the proportion of participants with at least one high-use episode of agonist ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- , respectively , relative risk @ -LSB- @ % CI @-@ -RSB- ; p = @ ) .